Plus Therapeutics Stock Performance
| PSTV Stock | USD 1.29 0.01 0.78% |
The company holds a Beta of 0.0786, which implies not very significant fluctuations relative to the market. As returns on the market increase, Plus Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Plus Therapeutics is expected to be smaller as well. At this point, Plus Therapeutics has a negative expected return of -0.0073%. Please make sure to check Plus Therapeutics' sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to decide if Plus Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Plus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Plus Therapeutics is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
Last Split Factor 1:15 | Dividend Date 2019-08-06 | Last Split Date 2023-05-01 |
1 | Acquisition by Andrew Sims of 4098 shares of Plus Therapeutics at 1.27 subject to Rule 16b-3 | 09/10/2024 |
2 | Acquisition by Hedrick Marc H of 197595 shares of Plus Therapeutics at 1.26 subject to Rule 16b-3 | 09/11/2024 |
3 | Acquisition by Hawkins Richard J of 6285 shares of Plus Therapeutics at 1.3543 subject to Rule 16b-3 | 09/12/2024 |
4 | Acquisition by Hawkins Richard J of 4000 shares of Plus Therapeutics at 1.499 subject to Rule 16b-3 | 09/13/2024 |
5 | Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting | 10/01/2024 |
6 | Acquisition by Clowes Howard of 3000 shares of Plus Therapeutics at 2.42 subject to Rule 16b-3 | 10/10/2024 |
7 | Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024 | 11/05/2024 |
8 | Organogenesis Tops Q3 Earnings and Revenue Estimates | 11/12/2024 |
9 | Plus Therapeutics GAAP EPS of -0.37 beats by 0.19, revenue of 1.45M beats by 0.31M | 11/14/2024 |
10 | What is HC Wainwrights Estimate for PSTV FY2028 Earnings | 11/20/2024 |
11 | Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases | 11/21/2024 |
12 | Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal ... | 11/25/2024 |
13 | Stem Cell Therapy Strategic Business Report 2024 - Allogeneic Stem Cell Therapy Segment is Expected to Reach US1 Billion by 2030 with a CAGR of a 16.7 | 12/02/2024 |
| Begin Period Cash Flow | 18.1 M |
Plus |
Plus Therapeutics Relative Risk vs. Return Landscape
If you would invest 144.00 in Plus Therapeutics on September 4, 2024 and sell it today you would lose (15.00) from holding Plus Therapeutics or give up 10.42% of portfolio value over 90 days. Plus Therapeutics is currently does not generate positive expected returns and assumes 5.7156% risk (volatility on return distribution) over the 90 days horizon. In different words, 50% of stocks are less volatile than Plus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Plus Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Plus Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Plus Therapeutics, and traders can use it to determine the average amount a Plus Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0013
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PSTV |
Estimated Market Risk
| 5.72 actual daily | 50 50% of assets are less volatile |
Expected Return
| -0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Plus Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Plus Therapeutics by adding Plus Therapeutics to a well-diversified portfolio.
Plus Therapeutics Fundamentals Growth
Plus Stock prices reflect investors' perceptions of the future prospects and financial health of Plus Therapeutics, and Plus Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Plus Stock performance.
| Return On Equity | -5.22 | ||||
| Return On Asset | -0.69 | ||||
| Profit Margin | (2.40) % | ||||
| Operating Margin | (2.89) % | ||||
| Current Valuation | 6.16 M | ||||
| Shares Outstanding | 5.9 M | ||||
| Price To Book | 3.76 X | ||||
| Price To Sales | 1.38 X | ||||
| Revenue | 4.91 M | ||||
| Gross Profit | (9.47 M) | ||||
| EBITDA | (12.69 M) | ||||
| Net Income | (13.32 M) | ||||
| Cash And Equivalents | 20.27 M | ||||
| Cash Per Share | 0.60 X | ||||
| Total Debt | 4.18 M | ||||
| Debt To Equity | 0.53 % | ||||
| Current Ratio | 2.81 X | ||||
| Book Value Per Share | (0.30) X | ||||
| Cash Flow From Operations | (12.85 M) | ||||
| Earnings Per Share | (2.37) X | ||||
| Market Capitalization | 7.61 M | ||||
| Total Asset | 11.39 M | ||||
| Retained Earnings | (480.5 M) | ||||
| Working Capital | (893 K) | ||||
About Plus Therapeutics Performance
Evaluating Plus Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Plus Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Plus Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (34.84) | (33.10) | |
| Return On Tangible Assets | (1.21) | (1.27) | |
| Return On Capital Employed | (20.15) | (19.15) | |
| Return On Assets | (1.17) | (1.23) | |
| Return On Equity | 9.88 | 10.37 |
Things to note about Plus Therapeutics performance evaluation
Checking the ongoing alerts about Plus Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Plus Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Plus Therapeutics generated a negative expected return over the last 90 days | |
| Plus Therapeutics has high historical volatility and very poor performance | |
| Plus Therapeutics may become a speculative penny stock | |
| Plus Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 4.91 M. Net Loss for the year was (13.32 M) with loss before overhead, payroll, taxes, and interest of (9.47 M). | |
| Plus Therapeutics currently holds about 20.27 M in cash with (12.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Plus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Stem Cell Therapy Strategic Business Report 2024 - Allogeneic Stem Cell Therapy Segment is Expected to Reach US1 Billion by 2030 with a CAGR of a 16.7 |
- Analyzing Plus Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Plus Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Plus Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Plus Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Plus Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Plus Therapeutics' stock. These opinions can provide insight into Plus Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.